SenzaGen AB:s årsredovisning för räkenskapsåret 2017 finns nu tillgänglig på svenska på bolagets hemsida, senzagen.com/investors/rapporter, och på bolagets kontor med adress Medicon Village, Scheelevägen 2, 223 81 Lund. För […]
We wish to thank Kemivärlden Biotech and Medicon Village for Thursday’s event “The Future of Swedish and Danish Life Science”, many interesting areas within precision medicine and big data were […]
We would like to extend a great thank you to all customers, partners, friends and collaborators for a great SOT and ToxExpo 2018! We had record numbers both in the […]
Presented at SOT, 2018 Johansson A, Agemark M, Gradin R, Larne O, Appelgren H, Forreryd A, Jerre A, Edwards A, Hoepflinger V, Burleson F, Gehrke H, Roggen E, Johansson H […]
Lund, den 7 Mars, 2018 – SenzaGen (Nasdaq First North: SENZA) meddelar idag att företaget har tecknat ett strategiskt viktigt licensavtal med Burleson Research Technologies Inc. (BRT). BRT kommer som […]
Lund, March 7, 2018 – SenzaGen (Nasdaq First North: SENZA) announces today that the company has signed a strategically important license agreement with the well renowned Burleson Research Technologies Inc. […]
Lund, March 7, 2018 – SenzaGen (Nasdaq First North: SENZA) today announced that the company has recruited Dr Gunilla Grundström as its new Chief Scientific Officer. She has more than […]
Lund, den 7 mars, 2018 – SenzaGen (Nasdaq First North: SENZA) meddelar idag att bolaget rekryterat dr Gunilla Grundström som ny Chief Scientific Officer. Hon har mer än tio års […]
SenzaGen tillkännager idag att forskningresultat från en studie som syftat till att evaluera ”conformal prediction” av GARD™ har publicerats i den högt ansedda vetenskapliga tidskriften Toxicology in Vitro. Forskningsresultaten visar att […]
SenzaGen announces today that research on the conformal prediction of the GARD™ assay has been published in the distinguished peer reviewed journal Toxicology in Vitro. The research presented in the […]
